|Articles|December 1, 2011

Animal Study Shows Delta-Tocotrienol Least Cardioprotective, Company Says

Tocotrienol isomers gamma-tocotrienol and alpha-tocotrienol may benefit those with high cholesterol-but delta-tocotrienol doesn’t, according to a new study.

Tocotrienol isomers gamma-tocotrienol and alpha-tocotrienol may benefit those with high cholesterol-but delta-tocotrienol doesn’t, says ingredients supplier Carotech (Edison, NJ), according to a new study.

The rabbit study was published in Molecular and Cellular Biochemistry and performed by researchers from the University of Connecticut School of Medicine. Rabbits were fed a cholesterol diet for 60 days. On the last 30 days, they were given either alpha-, gamma-, or delta-tocotrienols.

At the end of the study, blood cholesterol levels were significantly lower in the gamma- and alpha-tocotrienol groups (50% and 39%, respectively), while the company says that the delta-tocotrienol group showed no significant reductions.

Moreover, gamma- and alpha-tocotrienols were shown to improve cardiac function and to reduce myocardial infarct size in hypercholesterolemic hearts, while the delta form did not, the company says. (Gamma-tocotrienol showed the strongest effects here.)

“Each isomer in the tocotrienol family plays different roles in our health,” stated WH Leong, Carotech’s vice president, in a press release. “In terms of cardioprotection, this study once again proves that gamma- and alpha-tocotrienol play an important part in lowering blood cholesterol and protecting the heart from injuries following a heart attack. Contrary to the misinformation that one can find on the Internet, delta-tocotrienol is the least effective. This study is consistent with the researchers’ earlier findings published in [American Journal of Physiology in 2008].”

The company says the findings support its own ingredients, Tocomin and Tocomin SupraBio, which are described as full-spectrum tocotrienol complexes containing the highest levels of gamma and alpha-tocotrienols.


Related to this article

SupplySide Global Vitaquest
Live from SupplySide Global 2026, Nutritional Outlook’s Nicholas Jacobus speaks with Michael Anthonavage, VP of innovation at Vitaquest International, about the company’s 2027 consumer trends forecast and how it’s shaping supplement formulation.
Laurentia Bliss
Live from SupplySide Global 2026, Laurentia Bliss talks about new athlete-focused research on Magtein, ThreoTech’s brain-targeted magnesium ingredient, and upcoming innovations like effervescent tablets and gummies.
Klaus Neumann
Live from SupplySide Global 2026, Klaus Neumann talks about Concordix's chewable supplement line spanning beauty and gut-immune health, including BeautyBioti, a Skin & Hair Vitality Complex, and FortiBiotic.